文献速递治疗药物监测与药物基因组学特殊人群用药

巴西药品说明书中药物基因组学生物标志物信息的现状分析

Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels.
PubMed 文献 · Br J Clin Pharmacol · 2025-09-28

本综述分析了ANVISA批准的药品说明书中19个基因-药物对的PGx标注,这些配对在CPIC指南中有强烈或中等推荐调整初始剂量或被监管机构要求/推荐检测。PGx标注分散于10个部分中的7个,分类为检测要求5个、检测推荐5个、可操作PGx 4个和无PGx临床信息4个。ANVISA说明书与所选监管机构的PGx等级一致性差(κ<0.20),监管机构间不一致性也显著(Fleiss κ=0.08)。巴西人群PGx风险生物标志物频率范围<0.1%至10.8%,原住民PGx多样性广泛。作者建议ANVISA说明书中增加PGx部分。

要点

  • ANVISA说明书中PGx信息分散于多个部分,一致性差。
  • 监管机构间PGx推荐一致性低(Fleiss κ=0.08)。
  • 巴西原住民PGx多样性广泛,需关注特殊人群。

核心结论

  • ANVISA药品说明书中PGx标注与CPIC指南及所选监管机构一致性差。
  • 建议在ANVISA说明书中增加PGx部分以整合信息。

研究设计与样本

  • 综述分析ANVISA批准的药品说明书,针对19个基因-药物对,这些配对在CPIC指南中有强烈或中等推荐调整初始剂量或被监管机构要求/推荐检测。

主要发现

  • PGx标注分布于说明书10个部分中的7个。
  • PGx标注分类:检测要求5个,检测推荐5个,可操作PGx 4个,无PGx临床信息4个。
  • ANVISA说明书与所选监管机构PGx等级一致性差(所有配对Cohen's kappa κ<0.20)。
  • 监管机构间不一致性显著(Fleiss's kappa κ=0.08)。
  • 巴西代表性队列中PGx风险生物标志物频率范围<0.1%至10.8%。

临床怎么用

  • 临床药师应关注ANVISA说明书中PGx信息分散问题,整合使用。
  • 对于CPIC指南推荐调整剂量的基因-药物对,应优先考虑PGx检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review examines the PGx annotations in package inserts (bulas in Brazilian Portuguese) approved by ANVISA, the Brazilian Health Regulatory Agency, for 19 gene-drug pairs with strong or moderate recommendations for initial dosing alteration in the CPIC (Clinical Pharmacogenetic Implementation Consortion) guidelines and PGx testing required or recommended by health regulatory agencies listed in the PharmGKB Drug Label Annotations table. It is assumed that drug-gene pairs with these two features should be prioritized for adoption by the Brazilian Public Health System (SUS). PGx annotations were distributed across seven of the ten sections of the bulas and classified as PGx testing required (n = 5), PGx testing recommended (n = 5), actionable PGx (n = 4) and no PGx clinical information (n = 4). Pairwise comparison of assigned PGx levels in ANVISA bulas vs. the selected regulatory agencies revealed poor concordance (Cohen's kappa coefficient κ < 0.20 for all pairs); however, discordance among these agencies is also considerable (Fleiss's kappa coefficient κ = 0.08). The frequency of the examined PGx risk biomarkers in representative Brazilian cohorts range from <0.1% to 10.8%. Importantly, Native Americans (0.4% of the current Brazilian population), display wide PGx diversity, both interethnically and in relation to non-Indigenous Brazilians. The author suggests that addition of a PGx section to the ANVISA bulas would avoid dispersion of clinically relevant PGx information across sections, assure integration of this information with SUS determinations and prevent discrepancies across sections, as observed in the bulas for thiopurines.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Suarez-Kurtz G. Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels. Br J Clin Pharmacol. 2025. PMID: 41016862. doi:10.1002/bcp.70278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。